Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #7. ADB-FUBICA
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #59
Qian, Z; Hua, Z; Liu, C; Jia, W. Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances Forensic Toxicol., 1 Jan 2016, 34 (1), 133–143. 589 kB. https://doi.org/10.1007/s11419-015-0297-2 #3 GC,MS,NMR
Alam, RM; Keating, JJ. “Walking the nitrogen around the ring”: Chemical synthesis and spectroscopic characterization of novel 4‐, 5‐, 6‐, and 7‐azaindazole analogs of the synthetic cannabinoid receptor agonist MDMB‐PINACA Drug Test. Anal., 11 Nov 2021, 14 (2), 277-297. 4.1 MB. https://doi.org/10.1002/dta.3180 #3 MS,NMR,IR,UV
Wouters, E; Mogler, L; Cannaert, A; Auwärter, V; Stove, C. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐ tert ‐leucine Drug Test. Anal., 1 Aug 2019, 11 (8), 1183–1191. 1.4 MB. https://doi.org/10.1002/dta.2607 #17